Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Refractory or Relapsed Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Lethal Congenital Contracture Syndrome 2 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 11Rituximab 10Prednisone 8Lenalidomide 8Vincristine 7Doxorubicin 7Bendamustine Hydrochloride 6obinutuzumab 5Magnetic Resonance Spectroscopy 4fludarabine 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Cyclosporine 3Biopsy 3zanubrutinib 2fludarabine phosphate 2Radiotherapy 2Prednisolone 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Melphalan 2Gemcitabine 2Etoposide 2Cytarabine 2venetoclax 1umbralisib 1treosulfan 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Itraconazole × 30 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡